2月24日，力诺药包涨5.1%，截至发稿，报18.12元/股，成交1.07亿元，换手率2.48%，总市值44.08亿 元。 资料显示，山东力诺医药包装股份有限公司位于山东省济南市商河县玉皇庙镇政府驻地，成立日期2002 年3月1日，上市日期2021年11月11日，公司主营业务涉及特种玻璃的研发、生产及销售,致力于硼硅玻 璃的开发和应用。主营业务收入构成为：耐热玻璃57.02%，药用玻璃40.74%，材料销售及其他2.24%。 从力诺药包十大流通股东角度 数据显示，圆信永丰基金旗下1只基金重仓力诺药包。圆信永丰聚优A（010469）四季度减持7.74万股， 持有股数117.76万股，占基金净值比例为2.99%，位居第九大重仓股。根据测算，今日浮盈赚取约 103.63万元。 圆信永丰聚优A（010469）成立日期2021年4月16日，最新规模4.4亿。今年以来收益6.25%，同类排名 2020/5580；近一年收益34.56%，同类排名1837/4297；成立以来收益32.78%。 圆信永丰聚优A（010469）基金经理为肖世源。 截至发稿，肖世源累计任职时间8年251天，现任基金资产总规模20.69亿元，任职期 ...

1月22日，力诺药包涨1.58%，成交额9504.39万元。两融数据显示，当日力诺药包获融资买入额2023.35 万元，融资偿还803.63万元，融资净买入1219.72万元。截至1月22日，力诺药包融资融券余额合计1.95 亿元。 融资方面，力诺药包当日融资买入2023.35万元。当前融资余额1.94亿元，占流通市值的4.36%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，力诺药包1月22日融券偿还0.00股，融券卖出100.00股，按当日收盘价计算，卖出金额 1865.00元；融券余量1.21万股，融券余额22.57万元，超过近一年90%分位水平，处于高位。 资料显示，山东力诺医药包装股份有限公司位于山东省济南市商河县玉皇庙镇政府驻地，成立日期2002 年3月1日，上市日期2021年11月11日，公司主营业务涉及特种玻璃的研发、生产及销售,致力于硼硅玻 璃的开发和应用。主营业务收入构成为：耐热玻璃57.02%，药用玻璃40.74%，材料销售及其他2.24%。 截至9月30日，力诺药包股东户数1.76万，较上期增加58.60%；人均流通股13571股，较上期减少 36.94%。2025年1月- ...

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance and financial metrics, with a notable increase in stock price year-to-date, but a decline in revenue and net profit for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22% [2]. - The net profit attributable to shareholders for the same period was 50.88 million yuan, reflecting a year-on-year decline of 27.80% [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [3]. Stock Market Activity - On December 29, Linuo Pharmaceutical's stock rose by 2.11%, reaching 17.90 yuan per share, with a trading volume of 58.95 million yuan and a turnover rate of 1.40% [1]. - The company's market capitalization stands at 4.279 billion yuan [1]. - Year-to-date, the stock price has increased by 19.95%, with a 1.94% rise over the last five trading days, 5.05% over the last 20 days, and 3.71% over the last 60 days [1]. Shareholder Composition - The number of shareholders increased to 17,600 as of September 30, 2025, marking a 58.60% rise from the previous period [2]. - The average number of tradable shares per shareholder decreased by 36.94% to 13,571 shares [2]. - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed Fund and Green High Dividend Preferred Mixed Fund, among others [3].

12月23日，力诺药包跌1.48%，成交额4177.78万元。两融数据显示，当日力诺药包获融资买入额374.21 万元，融资偿还618.84万元，融资净买入-244.63万元。截至12月23日，力诺药包融资融券余额合计1.51 亿元。 融资方面，力诺药包当日融资买入374.21万元。当前融资余额1.51亿元，占流通市值的3.65%，融资余 额超过近一年70%分位水平，处于较高位。 截至9月30日，力诺药包股东户数1.76万，较上期增加58.60%；人均流通股13571股，较上期减少 36.94%。2025年1月-9月，力诺药包实现营业收入7.21亿元，同比减少13.22%；归母净利润5088.23万 元，同比减少27.80%。 分红方面，力诺药包A股上市后累计派现1.39亿元。近三年，累计派现9217.77万元。 机构持仓方面，截止2025年9月30日，力诺药包十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第六大流通股东，持股380.00万股，为新进股东。格林高股息优选混合A（015289）位 居第七大流通股东，持股314.33万股，为新进股东。圆信永丰医药健康A（006274）位居第十 ...

Core Insights - Linuo Pharmaceutical Packaging Co., Ltd. experienced a slight increase in stock price by 0.64% on November 12, with a trading volume of 66.55 million yuan [1] - The company reported a financing buy-in amount of 3.93 million yuan and a financing repayment of 8.51 million yuan on the same day, resulting in a net financing buy of -4.58 million yuan [1] - As of November 12, the total financing and securities lending balance for Linuo Pharmaceutical was 130 million yuan, which accounts for 3.12% of its circulating market value [1] Financing Overview - On November 12, Linuo Pharmaceutical had a financing buy-in of 3.93 million yuan, with a current financing balance of 130 million yuan, exceeding the 60th percentile level over the past year [1] - The company had no securities lending activity on November 12, with a securities lending balance of 0.00 shares, indicating a high level of inactivity in this area [1] Company Profile - Linuo Pharmaceutical, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [1] - The company's main business involves the research, production, and sales of special glass, focusing on the development and application of borosilicate glass [1] - The revenue composition of Linuo Pharmaceutical includes 57.02% from heat-resistant glass, 40.74% from pharmaceutical glass, and 2.24% from material sales and others [1] Financial Performance - As of September 30, 2025, Linuo Pharmaceutical reported a total revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, the number of shareholders for Linuo Pharmaceutical increased by 58.60% to 17,600 [2] - The average number of circulating shares per shareholder decreased by 36.94% to 13,571 shares [2] - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Core Insights - Linuo Pharmaceutical Packaging Co., Ltd. experienced a stock price increase of 1.00% on November 11, with a trading volume of 55.33 million yuan [1] - The company reported a financing net purchase of 378,300 yuan on the same day, with a total financing and securities balance of 134 million yuan [1] - The company’s main business includes the research, production, and sales of special glass, with a revenue composition of 57.02% from heat-resistant glass and 40.74% from medicinal glass [1] Financing and Trading Data - On November 11, Linuo Pharmaceutical had a financing purchase of 6.68 million yuan, with a current financing balance of 134 million yuan, representing 3.25% of its market capitalization [1] - The financing balance is above the 60th percentile level over the past year, indicating a relatively high position [1] - There were no short sales or repayments on the same day, with the short selling balance also at zero, placing it in the 90th percentile level over the past year [1] Financial Performance - For the period from January to September 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2] Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2] - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Group 1 - The core viewpoint of the news highlights the financial performance and stock trading activities of Linuo Pharmaceutical Packaging Co., Ltd. as of November 6, 2023, indicating a mixed outlook with a slight increase in stock price and notable financing activities [1][2] Group 2 - As of November 6, 2023, Linuo Pharmaceutical's stock price increased by 0.35%, with a trading volume of 45.19 million yuan [1] - The financing buy-in amount for Linuo Pharmaceutical on the same day was 6.55 million yuan, while the financing repayment was 3.89 million yuan, resulting in a net financing buy-in of 2.65 million yuan [1] - The total financing and securities balance for Linuo Pharmaceutical reached 142 million yuan, accounting for 3.47% of its market capitalization, which is above the 60th percentile level over the past year [1] - On the securities lending side, there were no shares sold or repaid on November 6, 2023, with a securities lending balance of 0, indicating a high level of inactivity in this area [1] Group 3 - As of September 30, 2023, the number of shareholders for Linuo Pharmaceutical increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2] - For the period from January to September 2023, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - Since its A-share listing, Linuo Pharmaceutical has distributed a total of 139 million yuan in dividends, with 92.18 million yuan distributed over the past three years [2] - As of September 30, 2023, new institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Core Viewpoint - The stock price of Linuo Pharmaceutical Packaging has experienced a decline recently, despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - Linuo Pharmaceutical Packaging Co., Ltd. is located in Shandong Province, established on March 1, 2002, and listed on November 11, 2021. The company specializes in the research, production, and sales of specialty glass, focusing on borosilicate glass development and application [2]. - The main business revenue composition includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [2]. Stock Performance - Year-to-date, the stock price has increased by 14.72%, but it has decreased by 2.62% over the last five trading days, 0.12% over the last 20 days, and 20.26% over the last 60 days [2]. - As of October 29, the stock price was reported at 17.12 CNY per share, with a market capitalization of 4.093 billion CNY [1]. Financial Performance - For the period from January to September 2025, Linuo Pharmaceutical Packaging reported a revenue of 721 million CNY, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.8823 million CNY, down 27.80% year-on-year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2]. - The company has distributed a total of 139 million CNY in dividends since its A-share listing, with 92.177 million CNY distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, new institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B (holding 3.8 million shares), Green High Dividend Preferred Mixed A (holding 3.1433 million shares), and Yuanxin Yongfeng Pharmaceutical Health A (holding 1.62 million shares) [3].

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance, with a year-to-date increase of 19.08% and a recent decline over the past 60 days of 17.88% [2] Company Overview - Linuo Pharmaceutical Packaging, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [2] - The company specializes in the research, production, and sales of specialty glass, focusing on borosilicate glass development and application [2] - Revenue composition includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [2] - The company operates within the pharmaceutical and biological industry, specifically in medical devices and consumables [2] Financial Performance - For the first half of 2025, Linuo Pharmaceutical reported revenue of 499 million yuan, a year-on-year decrease of 11.07% [2] - The net profit attributable to the parent company was approximately 40.97 million yuan, reflecting a year-on-year decline of 20.12% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 17.08% to 11,100 [2] - The average number of circulating shares per shareholder decreased by 12.16% to 21,522 shares [2] - Cumulative cash dividends since the company's A-share listing amount to 139 million yuan, with 92.18 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Guotai Junan Value Advantage Flexible Allocation Mixed Fund, which holds 5.90 million shares, a decrease of 1.55 million shares from the previous period [3] - Guotai Junan Innovation Growth Mixed Fund holds 2.87 million shares, down by 530,000 shares [3] - Guotai Junan Pharmaceutical Health Stock A is a new shareholder with 2.79 million shares [3]

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in financing and stock performance, with a notable decrease in revenue and net profit in the first half of 2025 [1][2]. Financing and Stock Performance - On October 9, Linuo Pharmaceutical's stock rose by 0.29%, with a trading volume of 64.94 million yuan [1]. - The financing buy-in amount for Linuo Pharmaceutical on the same day was 7.58 million yuan, while the financing repayment was 13.31 million yuan, resulting in a net financing outflow of 5.72 million yuan [1]. - As of October 9, the total financing and securities lending balance for Linuo Pharmaceutical was 161 million yuan, accounting for 3.90% of its market capitalization, indicating a high level compared to the past year [1]. Company Overview - Linuo Pharmaceutical, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [1]. - The company specializes in the research, production, and sales of specialty glass, focusing on the development and application of borosilicate glass [1]. - The revenue composition of Linuo Pharmaceutical includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [1]. Financial Performance - As of June 30, 2025, Linuo Pharmaceutical had 11,100 shareholders, an increase of 17.08% from the previous period [2]. - The company reported a revenue of 499 million yuan for the first half of 2025, a year-on-year decrease of 11.07%, and a net profit attributable to shareholders of 40.97 million yuan, down 20.12% year-on-year [2]. - Since its A-share listing, Linuo Pharmaceutical has distributed a total of 139 million yuan in dividends, with 92.18 million yuan distributed over the past three years [2]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Linuo Pharmaceutical, Guotai Junan's value advantage flexible allocation mixed fund held 5.90 million shares, a decrease of 1.55 million shares from the previous period [2]. - Guotai Junan's innovative growth mixed fund held 2.87 million shares, down by 530,000 shares, while Guotai Junan's pharmaceutical health stock A fund entered as a new shareholder with 2.79 million shares [2].